311 Frequency and acceptance of CDSS-generated STOPP/START signals - SI Table SI1.1. Continued. STOPP criteria (n=79) All countries Belgium (BE) Switzerland (CH) Ireland (IE) The Netherlands (NL) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) B 2. Verapamil or diltiazem with NYHA Class III or IV heart failure 2 50.0% 0 N/A 0 N/A 0 N/A 2 50.0% B 12. Aldosterone antagonists (e.g. spironolactone, eplerenone) with concurrent potassium-conserving drugs (e.g. ACEI’s, ARB’s, amiloride, triamterene) without monitoring of serum potassium 2 0% 0 N/A 2 0% 0 N/A 0 N/A C 4. Aspirin plus clopidogrel as secondary stroke prevention, unless the patient has a coronary stent(s) inserted in the previous 12 months or concurrent acute coronary syndrome or has a high grade symptomatic carotid arterial stenosis . 2 0% 0 N/A 0 N/A 1 0% 1 0% D 10. Neuroleptics as hypnotics, unless sleep disorder is due to psychosis or dementia 2 50.0% 1 0% 1 100% 0 N/A 0 N/A D 12. Phenothiazines as first-line treatment, since safer and more efficacious alternatives exist 2 0% 1 0% 0 N/A 0 N/A 1 0.0% J 6. Androgens (male sex hormones) in the absence of primary or secondary hypogonadism 2 0% 0 N/A 2 0% 0 N/A 0 N/A D 13. Levodopa or dopamine agonists for benign essential tremor 1 100% 0 N/A 1 100% 0 N/A 0 N/A E 1. Digoxin at a long-term dose greater than 125µg/ day if eGFR < 30 ml/min/1.73m2 1 0% 1 0% 0 N/A 0 N/A 0 N/A 4
RkJQdWJsaXNoZXIy MTk4NDMw